BIIB125
Preclinical
BiogenBIIB125 is one of 8 therapeutic programs targeting Neurodegeneration. It is currently in Preclinical.
1
Indications
0
Total Trials
0
Active Trials
7
Competitors
Pipeline
Status by Indication[1]
Indication
Competition
Competitive Landscape
11 competitors in Neurodegeneration
#DrugCompanyPhaseTrials
1Campath
GGenzyme, a Sanofi Company
Approved
Dayvigo
EisaiPhase 2
Ferriprox
Chiesi Farmaceutici S.p.A.Phase 2
F-18
BayerPhase 2
Namenda
AbbViePreclinical
Intropin
PfizerPreclinical
F-18-THK-5351
CChang Gung Memorial Hospital
Phase 2
BIIB125
BiogenPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Sources
References
- [1]Open Targets Platform — Drug–disease associations for BIIB125. EMBL-EBI & Wellcome Sanger Institute.
- [2]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical
- Company